`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`!
`
`"
`
`#
`
`$
`
`%
`
`%
`
`&
`
`'
`
`(
`
`NUVASIVE 1053
`NuVasive, Inc. v. Warsaw Orthopedic, Inc.
`IPR2013-00206
`IPR2013-00208
`
`NUVASIVE - EXHIBIT 2011
`Alphatec Holdings Inc. et al. v. NuVasive, Inc.
`IPR2019-00362
`
`

`

`Outline
`
`|.
`
`Executive Summary
`
`III. Market Plan
`
`Mission
`
`Objectives
`
`Strategies
`Tactics
`
`IV.
`
`Impact for the Future
`
`2
`
`{:ILIF mar-hat cg Plan
`
`II. Current Environment
`
`DLIF IS roR EVERY SURGEON
`)
`*
`+
`+
`+
`+
`,
`-
`,
`.
`/
`0
`1
`2
`3
`0
`4
`5
`6
`0
`
`
`
`
`8
`9
`9
`:
`;
`<
`=
`;
`>
`>
`
`
`
`
`
`
`
`
`
`
`
`?
`@
`A
`B
`C
`D
`E
`F
`C
`
`Discuss all competitors entering the arena
`
`7
`
`
`
`
`
`Confidential Information — Patent Prosecution Sensitive
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PX1 056-0002
`
`
`
`
`
`
`
`
`
`
`
`2
`
`MNUV0188195
`
`
`
`
`
`!
`
`"
`
`#
`
`$
`
`%
`
`%
`
`&
`
`'
`
`G
`
`

`

`H
`
`H
`
`I
`
`J
`
`K
`
`I
`
`L
`
`M
`
`N
`
`O
`
`O
`
`L
`
`L
`
`Our DLIF objectives to reverse this trend are to increase the % of.
`territories sellin DLIF to 40% 23% today by end of FY11 and
`complete 30,00 DLIF levels( ,500 today by end of FY12
`
`Qw
`
`To meet these objectives, we must execute on strategies of:
`1) Product Pipeline, 2) Training. and 3) Messaging
`Product: Execute time efficient launch of_ lateral QIate, begin shift to
`innovation With launch of flEleO unleash Innova ive new implant design
`Training: Continue focus on effective surgeon and sales training
`Messaging: Ex and awareness of DLIF and entire minimally invasive
`platform across
`LL stakeholders as a company
`
`The lateral market is here to stay and XLIF is negatively impacting
`MDT minimally invasive growth and share
`
`Executive Summary
`
`P
`
`L
`
`I
`
`DLIF is one piece of the fastest growin platform at MSB (>$200M in
`CY08 foriust minimally Invasive fusion
`
`::-LIF Marlil-ng Plan
`
`DLIF is roF. EVERY suRGEoi-i
`
`Confidential Information — Patent Prosecution Sensitive
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PX1056-OOO3
`
`
`
`
`
`
`
`
`
`
`
`3
`
`MNUV0188196
`
`
`
`
`
`!
`
`"
`
`#
`
`$
`
`%
`
`%
`
`&
`
`'
`
`Q
`
`

`

`.
`
`'3? Late-rat Plate '-
`(.i" {L
`"stream tNEi'u'iG-i '.
`0! "text C
`fN Kt Gen Implant
`
`\
`
`\
`Drive 40% of sales
`force to seii Ciydesdaie ‘-
`by end of Ft"? 1
`
`EILF IS I'L‘P. E‘.-'F
`R
`S
`T
`U
`T
`U
`V
`V
`W
`X
`W
`X
`Y
`Z
`
`Perform 30,000 DLiF
`levels by the end of
`F‘fiE {30. . lateral
`share}
`
`Confidential Information - Patent Prosecution Sensitive
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PX1 056-0004
`
`
`
`
`
`
`
`
`
`
`
`4
`
`MNUV0188197
`
`
`
`
`
`!
`
`"
`
`#
`
`$
`
`%
`
`%
`
`&
`
`'
`
`[
`
`

`

`Current Environment
`
`EILIf IS FOR EVERY SLIRGEmJ.
`\
`]
`N
`N
`N
`^
`^
`_
`_
`_
`_
`
`5-
`
`E'JLIF h‘afl-wi-Ag Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PX1 056-0005
`
`
`
`
`
`
`
`
`
`
`
`5
`
`MNUV0188198
`
`
`
`
`
`!
`
`"
`
`#
`
`$
`
`%
`
`%
`
`&
`
`'
`
`%
`
`

`

`- Complgx adult deggnnasas.
`'
`'
`I-Adjacent to'a previous fusion
`- Low-grade spondy
`
`$m
`
`Minimally Invasive but Powerful
`
`a
`
`a
`
`b
`
`i
`
`u
`
`k
`
`j
`
`w
`
`n
`
`o
`
`l
`
`m
`
`z
`
`y
`
`c
`
`d
`
`
`
`g
`
`{
`
`g
`
`e
`
`c
`
`p
`
`
`
`|
`
`f
`
`q
`
`
`
`}
`
`Aocess option from T6 to L5!
`
`DLlF 101
`
`Keylnformatlon
`
`Observed Applications
`
`' Launched: February 2007
`- Sets: 120 in field + 50in Dec '09
`
`- c‘rna Lateral Market Size: $35M
`- OY12 Lateral Market Size: $122M
`
`Construct ASPijjOneLevelj
`
`DLtF Procedural Portfolio
`
`_—-
`
`--
`
``
`
``
`
``
`
`DLIF is for every surgeon.
`Not new — been around for sometime!
`
`::-LIF Nari-wing Plan
`
`Longitude
`
`Biologilxa
`
`EMF I: run E'.-'a::'r' SURGEON
`
`‚
`
`ƒ
`
`„
`
`
`
`‚
`
`r
`
`s
`
`u
`
`D
`
`C
`
`t
`
`D
`
`s
`
`u
`
`E
`
`F
`
`~
`
`F
`
`o
`
`Pull through power (NIM, fixation, bio...)
`
`c
`
`
`
`
`>
`
`;
`
`
`
`<
`
`|
`
`
`•
`
`
`
`’
`
`‰
`
`”
`
`@
`
`ž
`
`†
`
`
`
` 
`
`–
`
`Š
`
`—
`
`Œ
`
`n
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`g
`
`™
`
`
`
`š
`
`‹
`
`
`
`˜
`
`
`
`Ž
`
`§
`
`¨
`
`©
`
`ª
`
`«
`
`¬
`
`¬
`
`h
`v
`…
`›
`
`<
`
`
`
`x
`
`
`‘
`
`|
`
`
`
`
`
`
`
`
`
`œ
`
`†
`
`‘
`
`ž
`
`‡
`
`‡
`
`ˆ
`
`’
`
`
`
`
`
`
`
`“
`
`Ÿ
`
`High growth market!
`
`Vital opportunity for representative differentiation
`
`€
`¦
`
`†
`
`£
`
`
`
`
`
`
`
`
`
`
`®
`
`¯
`
`
`°
`
`±
`
`
`­
`
`µ
`
`¢
`
`£
`
`¤
`
`
`
`
`
`¥
`
`
`
`
`
`>
`
`
`
`=
`
`>
`
`
`
`
`
`u
`
`
`
`
`
`ˆ
`
`¶
`
`¡
`
`·
`
`E
`
`n
`
`¹
`
`¸
`
`o
`
`D
`
`º
`
`g
`
`»
`
`;
`
`=
`
`=
`
`
`
`;
`
`Œ
`
`‹
`
`>
`
`
`
`ž
`
`
`
`²
`
`£
`
`¢
`
`¢
`
`³
`
`´
`
`³
`
`¨
`
`¦
`
`£
`
`¥
`
`¦
`
`£
`
`§
`
`¨
`
`
`
`Ÿ
`
`ž
`
`Ÿ
`
`
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`Confidential Information — Patent Prosecution Sensitive
`
`PX1056-0006
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`6
`
`MNUV0188199
`
`Û
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`á
`
`á
`
`â
`
`ã
`
`ã
`
`

`

`am
`ú
`
`
`
`
`Ø
`
`
`
`
`
`
`Ì
`ô
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Â
` 
`E
`Å
`
`Ü
`
`
`Ü
`ú
`
`
`ï
`
`ï
`û
`Ó
`
`
`
`
`
`
`!
`
`E
`
`"
`
`Í
`
`ô
`%
`
`Ð
`Â
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-0007
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`7
`
`MNUV0188200
`
`Û
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`&
`
`á
`
`'
`
`'
`
`á
`
`å
`
`
`õ
`
`ñ
`Õ
`
`h
`
`D
`
`
`
`ô
`
`s
`
`w
`
`
`
`
`
`
`
`~
`
`ð
`ð
`
`ñ
`
`C
`
`
`
`ë
`
`
`
`
`Ê
`
`Õ
`¿
`
`Ñ
`
`Ï
`
`Ö
`
`½
`
`
`
`Ó
`
`Ï
`
`Ù
`
`Í
`
`Õ
`
`Ë
`
`
`
`Ø
`
`ö
`
`
`
`Ö
`
`y
`
`#
`
`Ó
`
`þ
`Ò
`
`
`
`Ê
`
`
`
`Ñ
`
`Í
`
`×
`
`Ø
`
`Ö
`
`ÿ
`
`Õ
`
`Ò
`
`Ð
`
`¶
`
`Ë
`
`
`
`
`
`¸
`
`Ä
`
`
`
`Ï
`
`Î
`
`¹
`
`À
`
`º
`
`Ä
`
`Ò
`
`»
`
`Ñ
`
`Å
`
`·
`
`$
`
`Ä
`
`Ê
`
`Î
`
`Ì
`
`Market Financials to Date
`
`53 be
`
`4.4
`
`CYOS
`
`10,8
`
`1.01
`
`CYDE
`
`14
`
`CYOT
`
`13% MDT Share
`
`CYOB
`
`Clydesdale Launch
`
`F‘i"08 RTM Training
`
`New MedEd Strategy Implemented
`
`NIM & Patient Positioning incorporated
`
`Major
`Initiatives
`
`NIM Eclipse Launch
`
`Strategic Product Addition
`Clydesdale Size Extension
`Longitude Launched
`
`our is FOR Evens-5 SURGEON.
`
`w
`
`E
`
`~
`
`E
`
`ø
`
` 
`
`ù
`
`E
`
`j
`
`÷
`
`Ã
`
`¾
`
`ö
`
`Ù
`
`Â
`
`í
`
`î
`
`è
`
`õ
`
`ô
`
`ü
`
`Advanced DLIF Trainings held regionally
`
`Regional Sales Meetings
`
`.-...
`E(-8
`E)
`:I
`
`Ew>m
`
`0’:
`:-
`'0
`
`ont
`
`. EE
`
`ä
`
`ä
`
`ä
`
`ä
`
`ä
`
`ä
`
`ä
`
`ä
`
`ä
`
`T
`
`y
`
`ò
`
`ó
`
`Clydesdale Downclass
`
`c:-LIF Mametng Plan
`
`è
`
`é
`
`ê
`
`ò
`
`è
`
`ì
`
`Ù
`
`Ô
`
`æ
`
`ç
`
`ñ
`
`Sales Trainings
`
`NIM rep alignment
`
`New Tech Rep focus product
`
`Ð
`
`Ê
`
`Ì
`Ð
`
`Ê
`
`High Def Animation available
`
`û
`Ì
`
`Ø
`
`Ö
`
`Ì
`
`õ
`
`h
`
`ö
`
`Í
`
`Ø
`
`Ó
`
`Ö
`
`Ï
`
`u
`
`×
`
`Ê
`
`Ã
`
`À
`
`Ä
`
`F
`
`ù
`
`¡
`
`C
`
`r
`
`Ê
`
`h
`
`Ì
`
`i
`
`r
`
`Ð
`
`j
`
`k
`
`ü
`
`½
`
`ý
`
`ø
`Ö
`
`¾
`
`Ó
`
`Í
`
`Ø
`
`À
`
`¾
`
`Ö
`
`À
`
`Ã
`
`õ
`
`Ì
`
`À
`
`½
`
`Ë
`
`Ø
`
`Ì
`
`þ
`
`F
`Ð
`
`ö
`
`×
`
`ÿ
`
`ô
`
`Ö
`
`Õ
`
`Ç
`
`ô
`
`õ
`
`À
`
`½
`
`Ù
`
`Õ
`¾
`
`Ä
`
`Å
`
`Å
`
`Captured ~18% of market share since launch
`
`

`

`1.
`
`Innovative minimally invasive approach
`
`— Nuvasive pioneered the approach
`
`— Strategic focus lop MIS competitor
`
`2. Driving minimally invasive fusion market
`
`2005
`2005
`3
`131.5
`$109.4 3
`5
`E39 $313.13 5
`
`2GB?
`161.0
`53.1
`
`S
`3
`
`2003
`202.8
`105.3
`
`-
`
`I)
`.
`-..J'.-‘-
`
`2006
`54.1%
`7.8%
`
`2007
`46.1%“.
`15.2%
`
`2008
`41.8%
`21.8%
`
`Lateral Market Dynamics
`
`th Is roF. EVERY SURGEON
`N
`O
`O
`(
`)
`*
`+
`,
`(
`-
`.
`(
`)
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`/
`0
`1
`2
`3
`4
`5
`3
`6
`0
`7
`8
`9
`:
`9
`;
`;
`<
`<
`<
`<
`<
`<
`<
`<
`<
`<
`
`C:-L|F Lunar-w; Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-0008
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`8
`
`MNUV0188201
`
`Û
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`&
`
`á
`
`'
`
`á
`
`â
`
`

`

`Market Plan
`
`DLIF IS FOR EVERY SURGEON.
`®
`=
`>
`?
`@
`?
`A
`?
`B
`
`-:4
`
`[aLlF Nan-:u'ri-ng Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-0009
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`9
`
`MNUV0188202
`
`Û
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`&
`
`á
`
`'
`
`&
`
`á
`
`

`

`Leverage the exciting & innovative DLIF
`technology as a key growth driver for Medtronic's
`entire minimally invasive platform.
`
`DLIF IE roR EVERY SURGEON
`C
`a
`b
`c
`d
`c
`e
`f
`c
`g
`
`to
`
`£:-L|F l'.‘ar'-:al.¢-.9 Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1 056-001 0
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`MNUV0188203 10
`
`D
`
`E
`
`ú
`
`F
`
`G
`
`H
`
`H
`
`I
`
`F
`
`J
`
`ñ
`
`K
`
`L
`
`

`

`Objectives
`
`“it: Territories Selling
`83%
`
`EILF IS FOR EVERY SURGEON
`n
`M
`c
`d
`g
`g
`)
`)
`*
`N
`O
`P
`Q
`Q
`R
`S
`T
`U
`T
`U
`T
`U
`T
`U
`T
`V
`W
`X
`Y
`Z
`[
`\
`]
`^
`_
`
`Perform 30,000 DLIF levels by end of FY12
`7
`Estimated needs to drive 30% market share
`
`—
`
`5500 levels completed to date
`
`1
`
`I
`
`:1LlFr.tar'l.ai.-r.y Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-0011
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`MNUV0188204 11
`
`Û
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`&
`
`á
`
`'
`
``
`
`á
`
`

`

`DLIF Strategies
`
`PRODUCT PIPELINE
`
`Balance cadence of iterative and
`DISRUPTIVE technology
`
`th Is roR EVERY SLIRGEER-l.
`a
`b
`c
`c
`
`Create AWARENESS of the Medtronic
`DLIF offering a. the strength of the
`complete solution
`
`Develop best-in-class sales and
`surgeon training outlets along the
`entire learning CONTINUUM
`
`TRAINING
`
`MESSAGING
`
`‘2
`
`CJLIF Mar—wing: Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-0012
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`MNUV0188205 12
`
`D
`
`E
`
`ú
`
`F
`
`G
`
`H
`
`H
`
`I
`
`F
`
`d
`
`ñ
`
`K
`
`e
`
`

`

`Product Pipeline
`F‘i" 'l 0
`FT 1 'l
`
`_
`
`'
`
`__
`u [teen nut-"imam.
`m3“ :fifiQMi.
`.
`
`(2",
`
`I'l'lclyi‘le-idaie
`
`.
`
`'.
`
`I
`
`.
`
`..
`
`.
`
`I
`
`I
`
`I
`
`I
`
`-
`
`:
`
`I
`
`I
`
`i
`
`I
`
`:
`
`i
`
`1:.
`
`::-LIF Liana-fl r5; Plan
`
`I
`I
`3f3_
`
`X BR 1.5 'A
`
`-I_ _
`.
`Lsiqulnaie-Caga'_'
`
`I
`
`I
`
`.
`
`.
`.
`t
`l
`DLlF nstruments.
`Naéigal
`:.-..= I: =-:-i=. E'.'E=:'\"
`
`O Interbody,
`
`'
`
`I
`
`n Fixation
`A Enabling
`:
`' W
`
`- Activated
`- Hot prioritized
`
`_ f-loloianned
`
`...‘I
`
`7.
`
`.-"
`
`lncremental
`
`Revenue {SM}
`
`_
`
`.
`
`.
`
`'
`
`I
`
`.
`
`.
`
`Z
`
`I
`
`I
`
`2
`
`.
`
`Recommendations
`
`1. DLIF Dilators are in the pathway
`
`
`
`Immediate Focus on Navigated Dilators, Lateral Plate, NEMO, and Next
`2.
`Gen Implant
`
`3. How fast can we push things dangling at the finish line across? [Longer
`knife/bipolar, 40mm Clydesdale, “MAST Deformity" OR Long Throw
`Extender, Clydesdale Bone]
`
`Key Question: How to get projects too small to even be considered a project
`(e.g. Long Throw Extender, Longer Knife, 40mm Clydesdale) across?
`
`y
`
`º
`
`º
`
`¾
`
`»
`
`
`
`»
`
`À
`
`¿
`
`Â
`
`¸
`
`¼
`Ã
`
`º
`
`y
`
`Ä
`
`½
`
`¾
`
`¿
`
`À
`
`
`
`
`
`
`
`
`
`Ì
`
`
`
`Ð
`
`‘
`
`
`
`Ì
`
`ð
`
`Ê
`
`’
`
`Ã
`
`½
`
`
`
`Ù
`
`
`
`ˆ
`
`È
`
`„
`
`ƒ
`
`ƒ
`
`Ã
`
`½
`
`
`
`
`
`
`
`
`
`É
`
`Ñ
`
`Ï
`
`
`
`Ó
`
`Ð
`
`Ì
`
`Î
`
`Ì
`
`
`
`Æ
`
`Â
`
`½
`
`Ç
`
`Ã
`
`553-34
`
`g
`h
`h
`
`
`
`
`i
`j
`g
`
`k
`l
`m
`n
`o
`p
`r
`s
`t
`u
`v
`s
`w
`q
`
`Ù
`Õ
`À
`Å
`Ä
`Ã
`½
`Ç
`ý
`®
`õ
`ô
`Õ
`
`
`
`
`x
`o
`{
`|
`}
`~
`g
`
`
`Š
`
`
`
`‚
`ƒ
`„
`…
`†
`‡
`ˆ
`‰
`
`‹
`Œ
`
`Ž
`€
`
`y
`z
`Ä
`Ã
`Â
`Ç
`Ä
`Å
`Ì
`Ë
`õ
`Ù
`Õ
`Ê
`Ó
`Ê
`Ë
`Ì
`¶
`¶
`º
`·
`»
`º
`
`
`
`x
`W
`Ö
`õ
`Ù
`‘
`’
`
`
`
`”
`•
`r
`u
`}
`~
`q
`š
`›
`œ
`
`n
`ð
`“
`–
`
`
`
`Ä
`Ã
`Ù
`Õ
`±
`®
`—
`˜
`™
`¢
`¥
`¦
`Ã
`À
`¾
`þ
`ý
`õ
`Ö
`ö
`Ø
`Ö
`ö
`f
`f
`€
`
`
`
`¸
`g
`¹
`
`
`¨
`©
`ª
`«
`¬
`­
`®
`¯
`°
`±
`²
`³
`´
`µ
`¶
`g
`
`·
` 
`Ÿ
`%
`¡
`¢
`£
`£
`¤
`¥
`¦
`¥
`y
`§
`y
`À
`Â
`½
`Å
`Ä
`Ç
`º
`·
`º
`
`Å
`ö
`Â
`g
`Ï
`º
`·
`Ì
`œ
`¤
`º
`»
`
`¥
`
`¦
`
`y
`
`º
`
`§
`
`y
`
`·
`
`Í
`¥
`
`º
`
` 
`
`Ç
`
`›
`
`
`
`€
`
`
`
`
`
`º
`
`
`
`¶
`
`g
`
`§
`
`»
`
`z
`
`
`
`¼
`
`
`
`¸
`
`¹
`
`Õ
`
`º
`
`Ù
`
`¸
`
`y
`
` 
`
`Æ
`
`{
`
`½
`
`Ç
`
`m
`
`ý
`
`Ã
`
`Ç
`
`Î
`
`Í
`
`¼
`
`Ð
`
`Ñ
`
`Ò
`
`Ø
`
`Õ
`
`Ö
`
`»
`
`¡
`
`¢
`
`£
`
`£
`
`f
`
`ž
`Á
`Ê
`
`Ë
`
`Confidential Information — Patent Prosecution Sensitive
`
`MNUV0188206 13
`
`PX1056-0013
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`D
`
`E
`
`ú
`
`F
`
`G
`
`H
`
`H
`
`I
`
`F
`
`Ó
`
`ñ
`
`K
`
`Ô
`
`

`

`— D ance Leammg Modules on DLIF procedure and Iipsftricks
`— T -=Ining on Am:
`ced DLIF techniques
`— DLIF Tot-loo
`urrIn drive
`DUF sales tools}
`
`aiemlemphis To; Irru'rle nil-ale [raining needs
`camp:
`lions. etc
`
`Complete
`
`Ongoing
`
`Devetop best in class sates and surgeon training outiets
`along the entire teaming curve CONTINUUM
`
`ELF IS FOR E'Efi'r' SURGEER-J.
`ä
`ä
`ä
`ä
`ä
`ä
`ä
`Õ
`Ö
`×Ö
`×Ö
`×Ö
`x
`Û
`x
`Û
`x
`Û
`x
`Û
`Ø
`Ø
`Ø
`Ø
`Ù
`Ø
`Ú
`Ú
`
`focused ULIFI mngfot HIM reps
`
`W {'JLIF Mamet-19 Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`¼
`
`½
`
`¾
`
`¿
`
`À
`
`Á
`
`Â
`
`¾
`
`Ã
`
`À
`
`Ä
`
`Å
`
`Æ
`
`¾
`
`¿
`
`½
`
`Ç
`
`È
`
`Ä
`
`Ã
`
`À
`
`½
`
`¾
`
`É
`
`Ê
`
`Ë
`
`Ì
`
`Í
`
`Ë
`
`É
`
`Î
`
`Ï
`
`Ð
`
`Ì
`
`Ñ
`
`Ò
`
`Ë
`
`Ó
`
`Ï
`
`Í
`
`Ô
`
`Õ
`
`Ö
`
`×
`
`PX1056-OO14
`
`Ø
`
`Ù
`
`Ø
`
`Ú
`
`Õ
`
`NINUV0188207 14
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`á
`
`â
`
`â
`
`ã
`
`à
`
`ä
`
`K
`
`å
`
`

`

`Messaging
`
`Surgeon-FD
`— MIG .
`
`“min?
`]
`
`Nov '09
`
`Jun '10
`
`I
`
`— l_Jp:sa!ed DLIF markelmg materials on basic. and emerging le-zhniuues
`
`540.000
`(Budgeted)
`
`$5.000
`{Budgeted}
`
`iE-
`
`aLIF Mamet 11.1; Plan
`
`Create AWARENESS of the Medtronic DLIF offering and
`the strength of the compiete soiution
`.
`ioumnlad'u'enising campaign
`
`EILF IS FOR EVERY SURGEON
`W
`Ô
`?
`@
`A
`B
`=
`B
`?
`A
`?
`B
`=
`=
`?
`æ
`æ
`ç
`è
`è
`é
`è
`ê
`ë
`ë
`ì
`ë
`í
`í
`í
`í
`í
`í
`í
`í
`í
`í
`í
`
`Confidential Information — Patent Prosecution Sensitive
`
`î
`
`ï
`
`ð
`
`ñ
`
`ò
`
`ó
`
`ô
`
`ð
`
`õ
`
`ò
`
`ö
`
`÷
`
`ø
`
`ð
`
`ñ
`
`ï
`
`ù
`
`ú
`
`ö
`
`õ
`
`ò
`
`ï
`
`ð
`
`û
`
`ü
`
`ý
`
`þ
`
`ÿ
`
`ý
`
`û
`
`
`
`
`
`
`
`þ
`
`
`
`
`
`ý
`
`
`
`
`
`ÿ
`
`
`
`
`
`
`
`
`
`PX1 056-001 5
`
`
`
`
`
`
`
`
`
`

`
`
`
`NINUV0188208 15
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`á
`
`â
`
`â
`
`ã
`
`à
`
`â
`
`K
`
`
`
`

`

`Impact for the Future
`
`EILIf IS FOR EVERY SURGEON.
`9
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`“3-
`
`[iLlF NIF—wimp Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`î
`
`ï
`
`ð
`
`ñ
`
`ò
`
`ó
`
`ô
`
`ð
`
`õ
`
`ò
`
`ö
`
`÷
`
`ø
`
`ð
`
`ñ
`
`ï
`
`ù
`
`ú
`
`ö
`
`õ
`
`ò
`
`ï
`
`ð
`
`û
`
`ü
`
`ý
`
`þ
`
`ÿ
`
`ý
`
`û
`
`
`
`
`
`
`
`þ
`
`
`
`
`
`ý
`
`
`
`
`
`ÿ
`
`
`
`
`
`
`
`
`
`PX1056-0016
`
`
`
`
`
`
`
`
`
`

`
`
`
`MNUV0188209 16
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`á
`
`â
`
`â
`
`ã
`
`à
`
`
`
`K
`
`
`
`

`

`Financials for the Future
`
`DLIF I-E. rcuR E'Efi'r' SURGEDN
`*
`"
`)
`
`!
`
`l"-.|EMO
`DLIF Dilators
`Eng-age Line Extension Clydesdale Line Ext
`Surgeon Board
`Economic; Marketing
`Awareness Campaign
`
`3M
`
`Trainings
`National Course Update
`Custom Training Dope
`
`i'.-'
`
`ULIF ”weal-mg Plan
`
`CY10
`
`CY11
`
`CY12
`
`CY13
`
`Clydefidale ll
`
`Sensor Retractor
`
`Confidential Information — Patent Prosecution Sensitive
`
`î
`
`ï
`
`ð
`
`ñ
`
`ò
`
`ó
`
`ô
`
`ð
`
`õ
`
`ò
`
`ö
`
`÷
`
`ø
`
`ð
`
`ñ
`
`ï
`
`ù
`
`ú
`
`ö
`
`õ
`
`ò
`
`ï
`
`ð
`
`û
`
`ü
`
`ý
`
`þ
`
`ÿ
`
`ý
`
`û
`
`
`
`
`
`
`
`þ
`
`
`
`
`
`ý
`
`
`
`
`
`ÿ
`
`
`
`
`
`
`
`
`
`PX1056-OO17
`
`
`
`
`
`
`
`
`
`

`
`
`
`MNUV0188210 17
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`#
`
`á
`
`â
`
`â
`
`ã
`
`á
`
`#
`
`K
`
`$
`
`

`

`Elf IS roR EVERY SURGEON
`K
`K
`K
`K
`K
`K
`&
`'
`'
`*
`+
`%
`ò
`%
`(
`)
`(
`
`7 Implant stratification again key to
`hold premium at key accounts
`— Clinical evidence to position is key
`— Create surgeon advisory board to
`meet regularly and stayr ahead of
`where DLIF can take us.
`— Maintain focus on where DLIF works
`for us in the MIS portfolio and
`continue to innovate in this area
`
`— DLIF continues to be positioned as
`one piece of the MIS puzzle
`— Clinical evidence to position is key
`— Implant stratification becomes key to
`maintain pricing for oneitwo level
`— Clinical and economic evidence to
`justify construct benefit is needed
`
`Lateral approach falls out of favor
`
`Complex constructs become frowned
`upon by hospital administration
`
`implant pricing seriously impacted by
`health care reform
`
`NUVA beats to the punch on retractor,
`implant. or other technology
`
`iLIF Mme-5.5. Plan
`
`Confidential Information — Patent Prosecution Sensitive
`
`î
`
`ï
`
`ð
`
`ñ
`
`ò
`
`ó
`
`ô
`
`ð
`
`õ
`
`ò
`
`ö
`
`÷
`
`ø
`
`ð
`
`ñ
`
`ï
`
`ù
`
`ú
`
`ö
`
`õ
`
`ò
`
`ï
`
`ð
`
`û
`
`ü
`
`ý
`
`þ
`
`ÿ
`
`ý
`
`û
`
`
`
`
`
`
`
`þ
`
`
`
`
`
`ý
`
`
`
`
`
`ÿ
`
`
`
`
`
`
`
`
`
`PX1056-OO18
`
`
`
`
`
`
`
`
`
`

`
`
`
`MNUV01882‘l‘l 18
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`#
`
`á
`
`â
`
`â
`
`ã
`
`á
`
`á
`
`,
`
`-
`
`

`

`@launi:
`
`Questions?
`
`Confidential Information — Patent Prosecution Sensitive
`
`î
`
`ï
`
`ð
`
`ñ
`
`ò
`
`ó
`
`ô
`
`ð
`
`õ
`
`ò
`
`ö
`
`÷
`
`ø
`
`ð
`
`ñ
`
`ï
`
`ù
`
`ú
`
`ö
`
`õ
`
`ò
`
`ï
`
`ð
`
`û
`
`ü
`
`ý
`
`þ
`
`ÿ
`
`ý
`
`û
`
`
`
`
`
`
`
`þ
`
`
`
`
`
`ý
`
`
`
`
`
`ÿ
`
`
`
`
`
`
`
`
`
`PX1 056-001 9
`
`
`
`
`
`
`
`
`
`

`
`
`
`MNUV0188212 19
`
`Ü
`
`Ý
`
`Þ
`
`ß
`
`à
`
`á
`
`â
`
`â
`
`ã
`
`á
`
`ã
`
`,
`
`.
`
`